Artificial Organs

Introduction

Artificial organs: devices performing functions of biological organs when native organ fails. Need: 100,000+ patients on US transplant waiting list, ~17 die daily waiting. Types: temporary support (bridge-to-transplant), permanent replacement (destination therapy), or supplement (augmentation). Challenge: replicate complex biological functions with engineering solutions. Cost: $100,000-$1M+ per device/surgery. Impact: extends life for patients with no other options.

"We cannot yet grow organs, but we can build machines that perform their functions. The artificial organ is medicine's most ambitious engineering challenge—replacing millions of years of evolutionary design with human ingenuity." -- Biomedical engineer

Classification and Design Principles

Types

Fully mechanical: no biological components (artificial heart, dialysis). Bioartificial: mechanical + living cells (bioartificial liver, pancreas). Tissue-engineered: scaffold + cells (future direction). External: outside body (hemodialyzer, ECMO). Implantable: inside body (VAD, cochlear implant).

Design Requirements

Biocompatibility: blood contact requires anti-thrombotic surfaces. Durability: years of continuous operation. Power: reliable energy source (battery, transcutaneous). Size: fit within body cavity. Performance: match native organ output. Safety: failure modes must be manageable.

Bridge vs. Destination

Bridge-to-transplant: temporary support until donor organ available (weeks-months). Bridge-to-recovery: support while native organ heals. Destination therapy: permanent device for transplant-ineligible patients. Distinction important: affects device design, patient selection, regulatory pathway.

Blood-Material Interaction

Thrombosis: blood clots form on artificial surfaces (major challenge). Hemolysis: mechanical forces damage red blood cells. Infection: foreign surface colonized by bacteria. Solutions: anti-coagulation therapy, biocompatible coatings, smooth surfaces. Trade-off: anticoagulation prevents clots but increases bleeding risk.

Artificial Heart

Total Artificial Heart (TAH)

Concept: replaces both ventricles entirely. SynCardia TAH: only FDA-approved TAH (70 cc and 50 cc). Mechanism: pneumatic pumping (compressed air drives diaphragm). Output: 9.5 L/min (adequate cardiac output). Use: bridge-to-transplant (not destination therapy). Limitations: large external driver, percutaneous driveline, infection risk.

History

Jarvik-7 (1982): first permanent artificial heart (Barney Clark, survived 112 days). AbioCor (2001): first fully implantable TAH (no external connections). Challenges: durability, thrombosis, hemolysis, infection. Progress: incremental improvements, still not ideal destination therapy.

Design Approaches

Pulsatile: mimics natural heartbeat (diaphragm pump). Continuous flow: rotary pump (simpler, more durable, smaller). Pulsatile advantage: physiologic pulse (may be better for organ perfusion). Continuous advantage: fewer moving parts (more reliable). Current trend: continuous flow dominating.

Performance Requirements

Ventricular Assist Devices

Concept

VAD: pump assists (not replaces) failing ventricle. LVAD (left ventricular assist device): most common (left heart failure). RVAD: right ventricular support. BiVAD: both ventricles. Function: unloads ventricle, increases cardiac output. Implanted: inside pericardium, driveline exits through skin.

Pump Technologies

Axial flow: impeller rotates in tube (HeartMate II). Centrifugal flow: impeller spins in housing (HeartWare HVAD, HeartMate 3). Magnetic levitation: impeller suspended by magnets (no bearing wear). Speed: 6,000-15,000 RPM. Flow: 3-10 L/min (adjustable).

HeartMate 3

Current generation: fully magnetically levitated centrifugal pump. Size: 80 grams (pump only). Flow: 3-10 L/min. Artificial pulse: periodic speed changes create pulsatility. Results: 2-year survival >70% (destination therapy). Complications: driveline infection (~15%), stroke (~10%), GI bleeding (~20%).

Clinical Outcomes

Bridge-to-transplant: >90% survival to transplant. Destination therapy: 50-70% 2-year survival. Improvement: dramatic increase in exercise capacity, quality of life. Limitation: driveline infection, stroke, bleeding remain significant issues. Future: fully implantable (no driveline), wireless power transfer.

Complications

Thrombosis: pump thrombosis requires emergent exchange. Bleeding: anticoagulation + acquired von Willebrand syndrome. Infection: driveline exit site (chronic, difficult to eradicate). Stroke: 10-15% risk (thromboembolic or hemorrhagic). Right heart failure: LVAD unloading reveals RV weakness.

Artificial Kidney

Hemodialysis

Principle: blood pumped through semi-permeable membrane (dialyzer). Toxin removal: diffusion down concentration gradient (urea, creatinine, potassium). Fluid removal: ultrafiltration (pressure-driven). Duration: 3-4 hours, 3x/week. Limitation: intermittent (toxins accumulate between sessions).

Peritoneal Dialysis

Principle: peritoneal membrane as natural dialyzer. Fluid: dialysate instilled into abdomen, exchanged 4-5x/day (or overnight with cycler). Advantage: home-based, continuous, preserves residual function longer. Disadvantage: peritonitis risk, protein loss, membrane failure over years.

Wearable Artificial Kidney (WAK)

Concept: miniaturized hemodialysis worn on body. Continuous: 24/7 operation (more physiologic than intermittent). Size: belt-mounted (~5 kg). Sorbent: regenerates dialysate (reduces water requirement). Status: clinical trials (University of Washington). Promise: improved quality of life, better toxin clearance.

Implantable Artificial Kidney

Concept: silicon nanopore membrane + living kidney cells implanted. Hemofilter: removes toxins via pressure-driven filtration. Bioreactor: tubular cells reabsorb water, electrolytes (mimic natural kidney). Power: blood pressure-driven (no battery needed). Status: preclinical (Kidney Project, UCSF). Timeline: 5-10 years to clinical trials.

Artificial Liver Support

Liver Functions

Detoxification: removes albumin-bound toxins (bilirubin, bile acids). Synthesis: produces clotting factors, albumin, complement. Metabolism: drug metabolism, glucose regulation. Complexity: >500 functions (most complex organ to replace). Challenge: no single device replicates all functions.

Albumin Dialysis (MARS)

Molecular Adsorbent Recirculating System: removes albumin-bound toxins. Mechanism: albumin-enriched dialysate binds toxins across membrane. Regeneration: charcoal and resin columns clean albumin for reuse. Application: bridge-to-transplant in acute liver failure. Evidence: improves biochemistry, survival benefit debated.

Bioartificial Liver (BAL)

Concept: hollow-fiber bioreactor containing hepatocytes. Blood/plasma: flows through fibers, exchanges metabolites with cells. Cell source: porcine hepatocytes (most advanced), human hepatocyte lines. Function: detoxification + limited synthetic function. Status: clinical trials (HepatAssist, ELAD). Challenge: maintaining cell viability, sufficient cell mass.

Challenges

Complexity: liver performs too many functions for single device. Cell mass: need 200-400 grams of hepatocytes (equivalent to ~20% liver). Viability: maintaining cells functional outside body (days-weeks). Immunogenicity: porcine cells may trigger immune response. Status: no FDA-approved artificial liver device.

Artificial Lung (ECMO)

Extracorporeal Membrane Oxygenation

Principle: blood pumped through membrane oxygenator outside body. Gas exchange: O2 diffuses into blood, CO2 diffuses out. Configuration: VV-ECMO (respiratory support), VA-ECMO (cardiac + respiratory). Duration: days to weeks (bridge-to-recovery or transplant). Application: severe ARDS, cardiac failure, bridge-to-transplant.

Oxygenator Design

Membrane: polymethylpentene (PMP) hollow fibers. Surface area: 1.5-2.5 m² (comparable to natural lung ~70 m²). Blood flow: 3-7 L/min. Gas exchange: O2 delivery ~250 mL/min, CO2 removal ~200 mL/min. Priming volume: 200-500 mL. Replacement: every 2-4 weeks (clot formation, membrane degradation).

Intracorporeal Lung Assist

Concept: oxygenator implanted inside body (vena cava). Size: smaller than external ECMO. Advantage: ambulatory patients (improved quality of life). Device: Hemolung (ALung Technologies) for CO2 removal. Limitation: limited O2 delivery (better for CO2 removal). Status: clinical trials.

Challenges

Thrombosis: blood-membrane interface activates clotting. Hemolysis: mechanical forces damage red cells. Infection: percutaneous cannulae (major risk). Bleeding: anticoagulation required. Duration limit: membrane degradation, complications increase with time.

Artificial Pancreas

Closed-Loop Insulin Delivery

Components: continuous glucose monitor + insulin pump + control algorithm. Function: automated insulin delivery based on glucose readings. Algorithm: PID (proportional-integral-derivative) or MPC (model predictive control). Commercial: Medtronic 780G, Tandem Control-IQ, Omnipod 5.

Control Algorithm

Input: CGM glucose reading (every 5 minutes)Target: 100-120 mg/dL (adjustable)Response: increase/decrease insulin delivery rateMeal announcement: user inputs carbohydrate estimateSafety: suspend insulin if glucose droppingLimitation: insulin absorption lag (15-30 minutes)

Dual-Hormone Systems

Insulin + glucagon: glucagon raises glucose when dropping. Advantage: better hypoglycemia prevention. Challenge: glucagon stability (requires frequent replacement). Status: research prototypes (iLet Bionic Pancreas in trials). Promise: more physiologic glucose control.

Islet Cell Transplantation

Biological approach: transplant insulin-producing cells. Source: cadaveric donor pancreas or stem cell-derived. Challenge: immune rejection (requires immunosuppression). Encapsulation: protect islets in biocompatible membrane (avoid immunosuppression). Status: clinical trials (ViaCyte, Vertex). Promise: cure for type 1 diabetes.

Bioartificial Organs

Concept

Combine mechanical device with living cells. Advantage: cells perform biological functions no machine can replicate. Challenge: maintaining cell viability, function, and sterility. Examples: bioartificial liver, pancreas, kidney. Approach: hollow-fiber bioreactors housing cells.

Cell Sources

Primary cells: best function but limited supply (cadaveric). Cell lines: immortalized, unlimited supply, reduced function. Xenogeneic: animal cells (porcine), immunogenicity concerns. Stem cell-derived: iPSCs differentiated to target cell type (emerging). Challenge: sufficient cell mass with adequate function.

Bioreactor Design

Hollow fiber: blood flows through fibers, cells outside (most common). Flat plate: cells on membrane, blood flows over surface. Encapsulation: cells in hydrogel beads (alginate). Perfusion: continuous flow maintains cell viability. Mass transfer: oxygen delivery limits cell density.

Immunoprotection

Semi-permeable membrane: allows nutrient/waste exchange, blocks immune cells. Pore size: <0.2 µm (excludes immune cells, antibodies). Challenge: membrane fouling, thickness limits diffusion. Duration: weeks to months (membrane degradation). Improvement: biocompatible coatings, anti-inflammatory modifications.

Blood Substitutes

Hemoglobin-Based Oxygen Carriers (HBOCs)

Concept: purified hemoglobin solution carries oxygen. Source: human (outdated blood), bovine, recombinant. Problem: free hemoglobin causes vasoconstriction (nitric oxide scavenging). Modification: PEGylation, polymerization, cross-linking reduce toxicity. Status: limited approval (South Africa, Russia), not FDA-approved.

Perfluorocarbon Emulsions (PFCs)

Concept: synthetic molecules dissolve large quantities of oxygen. Mechanism: dissolved O2 (not bound like hemoglobin). Advantage: synthetic, no disease transmission, long shelf life. Disadvantage: requires high FiO2, short circulation time. Status: limited clinical use (specific surgical applications).

Clinical Need

Blood shortage: chronic, worsening with aging population. Emergency: remote areas, military settings without blood banks. Shelf life: RBCs expire in 42 days (logistic challenge). Universal donor: blood substitutes work regardless of blood type. Challenge: no substitute matches natural red blood cell function.

Engineering Challenges

Biocompatibility

Blood contact: thrombosis on every artificial surface. Anticoagulation: required but increases bleeding risk. Coatings: heparin, PEG, zwitterionic polymers reduce clotting. Endothelialization: growing endothelial cells on device surfaces (best long-term solution). Duration: current coatings last weeks-months.

Power Supply

Implantable devices: require reliable, long-lasting power. Battery: lithium-ion (limited capacity, replacement needed). Transcutaneous energy transfer (TET): wireless power through skin. Energy harvesting: body heat, motion, glucose fuel cells. Goal: eliminate percutaneous drivelines (infection source).

Durability

Heart: 100,000 beats/day × 365 × 10 years = 365 million cycles. Kidney: continuous 24/7 operation for years. Wear: bearing surfaces, membrane degradation. Materials: titanium, ceramic bearings, polymer membranes. Testing: accelerated fatigue testing (simulate years in weeks).

Miniaturization

Size constraints: must fit in body cavity or be wearable. Trade-off: smaller = less surface area = reduced performance. Solution: nanotechnology, advanced membranes, efficient designs. Goal: implantable kidney (~coffee cup size), wearable lung.

Future Directions

Xenotransplantation

Genetically modified pig organs: edited to reduce human immune rejection. Gene editing: CRISPR removes pig antigens, adds human genes. First human transplant: pig heart (2022, University of Maryland). Challenge: long-term rejection, zoonotic virus risk. Promise: unlimited organ supply.

3D Bioprinting

Print organs: layer-by-layer deposition of cells and matrix. Vascularization: print blood vessel networks within organ. Status: simple tissues (skin, cartilage) printed, complex organs (heart, kidney) years away. Challenge: achieving sufficient cell density, vascularization, function.

Organoids

Self-organizing: stem cells form mini-organs in culture. Types: brain, kidney, liver, intestine organoids developed. Application: drug testing, disease modeling, potentially transplantable. Limitation: small size (~mm), no vascularization. Timeline: therapeutic organoids decades away.

Decellularized Organs

Process: remove all cells from donor organ (detergent perfusion). Result: acellular scaffold with preserved vasculature. Recellularization: seed with patient's own cells (avoid rejection). Status: animal studies (heart, lung, kidney). Challenge: complete recellularization with functional cells.

References

• Copeland, J. G., Smith, R. G., Arabia, F. A., et al. "Cardiac Replacement with a Total Artificial Heart as a Bridge to Transplantation." New England Journal of Medicine, vol. 351, no. 9, 2004, pp. 859-867.
• Mehra, M. R., Uriel, N., Naka, Y., et al. "A Fully Magnetically Levitated Left Ventricular Assist Device." New England Journal of Medicine, vol. 380, no. 15, 2019, pp. 1618-1627.
• Humes, H. D., Fissell, W. H., and Tiranathanagul, K. "The Future of Hemodialysis Membranes." Kidney International, vol. 69, no. 7, 2006, pp. 1115-1119.
• Griffith, B. P., Goerlich, C. E., Singh, A. K., et al. "Genetically Modified Porcine-to-Human Cardiac Xenotransplantation." New England Journal of Medicine, vol. 387, no. 1, 2022, pp. 35-44.
• Ott, H. C., Matthiesen, T. S., Goh, S. K., et al. "Perfusion-Decellularized Matrix: Using Nature's Platform to Engineer a Bioartificial Heart." Nature Medicine, vol. 14, no. 2, 2008, pp. 213-221.